The Janssen Pharmaceutical Companies of Johnson & Johnson Company CyberSecurity Posture
http://www.janssen.com
At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Arterial Hypertension. Visit us: www.janssen.com Follow us: @JanssenGlobal on Twitter and Instagram Watch our videos on our YouTube channel: http://bit.ly/1LY2xQ5
Company Details
janssen-pharmaceutical-companies-of-johnson-and-johnson
14,253
1,062,040
3254
http://www.janssen.com
0
THE_2598635
In-progress
JPCJJ Risk Score (AI oriented)Between 750 and 799
JPCJJ Global Score (TPRM)XXXX
Description: The Maine Office of the Attorney General reported that Johnson & Johnson, Inc. experienced an external system breach (hacking) on August 16, 2024, affecting 3,225 individuals in total, including 3 residents of Maine. The breach was discovered on August 17, 2024, and individuals affected were offered 12 months of identity theft protection through Equifax Identity Defense.
Description: Johnson & Johnson, along with other companies like CVS Health and Walgreens, has been involved in opioid settlements due to their role in the addiction crisis. The article highlights concerns about the misuse of settlement funds, which were intended to address the opioid crisis but are being diverted to other purposes. This misuse includes spending on unrelated projects like road repairs and jail body scanners, rather than helping those affected by addiction. The misallocation of these funds has led to widespread concern and advocacy for better oversight.
Description: The home addresses of hundreds of Irish people had been published online in a data breach by a pharmaceutical company. The error left people vulnerable to hackers as the company also shared email addresses that may be linked to other online accounts.
Description: Johnson & Johnson is facing a **17% surge in lawsuits** (now **73,570+ cases**) alleging its talc-based baby powder causes cancer, following a failed attempt to force a **$9 billion global settlement** through bankruptcy court. A recent California jury awarded **$966 million** to a deceased woman’s family, linking her cancer to long-term baby powder use. Analysts predict total payouts could exceed **$11 billion**, with J&J already spending **$3 billion** on prior settlements. The company withdrew the product in 2023 but continues to deny liability, claiming talc is safe. Repeated legal defeats—including a bankruptcy judge rejecting its Chapter 11 strategy—have forced J&J back into state and federal courts, where upcoming trials (starting next month) risk further billion-dollar verdicts. The litigation threatens **reputational damage, financial strain (projected $11B+), and operational disruption**, as J&J defends cases across multiple jurisdictions while its Kenvue spinoff shares liability. State juries have repeatedly ruled against J&J, though some awards were later reduced on appeal. The escalating caseload (potentially **93,000+ claims**) compounds legal costs and public scrutiny, undermining trust in the brand.
No incidents recorded for The Janssen Pharmaceutical Companies of Johnson & Johnson in 2025.
No incidents recorded for The Janssen Pharmaceutical Companies of Johnson & Johnson in 2025.
No incidents recorded for The Janssen Pharmaceutical Companies of Johnson & Johnson in 2025.
JPCJJ cyber incidents detection timeline including parent company and subsidiaries
At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Arterial Hypertension. Visit us: www.janssen.com Follow us: @JanssenGlobal on Twitter and Instagram Watch our videos on our YouTube channel: http://bit.ly/1LY2xQ5
Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching t
Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the pa
At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently addre
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out mor
We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by list
The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worl
The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic
At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important
As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portf
.png)
The vaccine developer Janssen is examining the closure of its plant in Bern-Bümpliz. On Tuesday, it launched a consultation process with...
Johnson & Johnson (JNJ +0.21%) is a behemoth in the healthcare sector. The iconic company owns a diversified portfolio of innovative...
Nearly a year after a jury decided that Johnson & Johnson should be fined just over $150 million, a judge has upped the penalty more than...
STORY HIGHLIGHTS. Janssen Biotech bought 176 acres in the Wilson Corporate Park. The purchase is part of a $1 billion investment plan.
We're surfacing patterns in data to discover and deliver new treatments more efficiently. jjim-photo-writingonglass-11-4954.jpg...
We are committed to providing goods and services in a manner that is accessible for persons with disabilities and in accordance with the...
Three executives whose combined careers include working at companies including Amgen, AstraZeneca, The Janssen Pharmaceutical Companies of...
Johnson & Johnson today announced its pharmaceutical business segment will adopt the Johnson & Johnson brand name in Ireland. Janssen...
'Janssen' will no longer be seen on drug labels following the Johnson & Johnson brand name adoption.
Explore insights on cybersecurity incidents, risk posture, and Rankiteo's assessments.
The official website of The Janssen Pharmaceutical Companies of Johnson & Johnson is http://www.janssen.com.
According to Rankiteo, The Janssen Pharmaceutical Companies of Johnson & Johnson’s AI-generated cybersecurity score is 795, reflecting their Fair security posture.
According to Rankiteo, The Janssen Pharmaceutical Companies of Johnson & Johnson currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.
According to Rankiteo, The Janssen Pharmaceutical Companies of Johnson & Johnson is not certified under SOC 2 Type 1.
According to Rankiteo, The Janssen Pharmaceutical Companies of Johnson & Johnson does not hold a SOC 2 Type 2 certification.
According to Rankiteo, The Janssen Pharmaceutical Companies of Johnson & Johnson is not listed as GDPR compliant.
According to Rankiteo, The Janssen Pharmaceutical Companies of Johnson & Johnson does not currently maintain PCI DSS compliance.
According to Rankiteo, The Janssen Pharmaceutical Companies of Johnson & Johnson is not compliant with HIPAA regulations.
According to Rankiteo,The Janssen Pharmaceutical Companies of Johnson & Johnson is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.
The Janssen Pharmaceutical Companies of Johnson & Johnson operates primarily in the Pharmaceutical Manufacturing industry.
The Janssen Pharmaceutical Companies of Johnson & Johnson employs approximately 14,253 people worldwide.
The Janssen Pharmaceutical Companies of Johnson & Johnson presently has no subsidiaries across any sectors.
The Janssen Pharmaceutical Companies of Johnson & Johnson’s official LinkedIn profile has approximately 1,062,040 followers.
The Janssen Pharmaceutical Companies of Johnson & Johnson is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.
No, The Janssen Pharmaceutical Companies of Johnson & Johnson does not have a profile on Crunchbase.
Yes, The Janssen Pharmaceutical Companies of Johnson & Johnson maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/janssen-pharmaceutical-companies-of-johnson-and-johnson.
As of December 11, 2025, Rankiteo reports that The Janssen Pharmaceutical Companies of Johnson & Johnson has experienced 4 cybersecurity incidents.
The Janssen Pharmaceutical Companies of Johnson & Johnson has an estimated 5,413 peer or competitor companies worldwide.
Incident Types: The types of cybersecurity incidents that have occurred include Breach.
Total Financial Loss: The total financial loss from these incidents is estimated to be $0.
Detection and Response: The company detects and responds to cybersecurity incidents through an third party assistance with opioid policy institute, third party assistance with popular democracy, and third party assistance with equifax identity defense, and third party assistance with legal defense teams, third party assistance with bankruptcy advisors (failed attempts), third party assistance with public relations firms, and containment measures with product withdrawal (2023), containment measures with replacement with cornstarch-based alternative, containment measures with litigation defense strategy, and remediation measures with proposed $9b global settlement (rejected), remediation measures with preparation for upcoming trials, remediation measures with federal case consolidation (nj district court), and communication strategy with public statements denying talc-asbestos link, communication strategy with emphasis on 100+ years of 'safe use', communication strategy with criticism of lawsuit 'volume over merit'..
Title: Pharmaceutical Company Data Breach
Description: The home addresses of hundreds of Irish people had been published online in a data breach by a pharmaceutical company. The error left people vulnerable to hackers as the company also shared email addresses that may be linked to other online accounts.
Type: Data Breach
Title: Misuse of Opioid Settlement Funds
Description: State attorneys general won billions of dollars in opioid settlements from drug companies accused of fueling the addiction crisis. Concerns have arisen that the settlement funds are not being used for their intended purposes. Advocacy groups are proposing a crowdsourced database to identify potential examples of misuse and prompt attorneys general to investigate.
Type: Financial Misuse
Motivation: Financial Gain
Title: Johnson & Johnson External System Breach
Description: Johnson & Johnson, Inc. experienced an external system breach (hacking) affecting 3,225 individuals, including 3 residents of Maine.
Date Detected: 2024-08-17
Type: Data Breach
Attack Vector: Hacking
Title: Johnson & Johnson Faces Surge in Baby Powder Cancer Lawsuits After Failed Bankruptcy Settlement Attempt
Description: Johnson & Johnson (J&J) has experienced a 17% increase in new lawsuits (now totaling ~73,570) alleging its talc-based baby powder causes cancer, following the rejection of its latest bankruptcy-driven global settlement attempt. The company withdrew the product in 2023 but continues to face escalating litigation costs, with predictions of up to 93,000 cases and potential payouts exceeding $11 billion. Juries have repeatedly ruled against J&J, awarding billions in damages (e.g., $966M in a recent California case), though some verdicts were later reduced or overturned on appeal. The company maintains talc is safe and refuses to pay beyond its prior $9B offer, while preparing for new trials in state and federal courts.
Date Publicly Disclosed: 2024-10-01T00:00:00Z
Type: Product Liability Litigation
Motivation: Financial Gain (Plaintiffs)Corporate AccountabilityConsumer Protection
Common Attack Types: The most common types of attacks the company has faced is Breach.
Data Compromised: Home addresses, Email addresses
Customer Complaints: ['Families affected by the overdose crisis', 'Recovery and harm reduction advocates', 'Policy experts', 'Researchers following the cash']
Identity Theft Risk: High
Operational Impact: Increased litigation workloadReputation damageResource diversion to legal defenseProduct withdrawal (2023)
Customer Complaints: 73,570+ lawsuits (as of 2024-09-30)
Brand Reputation Impact: Severe damage due to cancer allegationsLoss of consumer trustNegative media coverageWithdrawal of iconic product
Legal Liabilities: Mass tort litigationJury awards (e.g., $966M in 2024)Potential federal/federal trialsState-level lawsuits (CA, PA, GA, IL, FL)
Average Financial Loss: The average financial loss per incident is $0.00.
Commonly Compromised Data Types: The types of data most commonly compromised in incidents are Home Addresses, Email Addresses and .
Entity Type: Pharmaceutical Company
Industry: Pharmaceutical
Location: Ireland
Customers Affected: Hundreds
Entity Name: State Governments
Entity Type: Government
Industry: Public Sector
Location: Multiple States
Entity Name: Johnson & Johnson, Inc.
Entity Type: Corporation
Industry: Healthcare
Customers Affected: 3225
Entity Name: Johnson & Johnson
Entity Type: Public Multinational Corporation
Industry: Pharmaceuticals, Consumer Goods, Healthcare
Location: New Brunswick, New Jersey, USA
Size: ~152,700 employees (2023)
Customers Affected: 73,570+ plaintiffs (as of 2024-09-30)
Entity Name: Kenvue (J&J spinoff)
Entity Type: Subsidiary
Industry: Consumer Health
Third Party Assistance: Opioid Policy Institute, Popular Democracy.
Third Party Assistance: Equifax Identity Defense
Third Party Assistance: Legal Defense Teams, Bankruptcy Advisors (Failed Attempts), Public Relations Firms.
Containment Measures: Product withdrawal (2023)Replacement with cornstarch-based alternativeLitigation defense strategy
Remediation Measures: Proposed $9B global settlement (rejected)Preparation for upcoming trialsFederal case consolidation (NJ District Court)
Communication Strategy: Public statements denying talc-asbestos linkEmphasis on 100+ years of 'safe use'Criticism of lawsuit 'volume over merit'
Third-Party Assistance: The company involves third-party assistance in incident response through Opioid Policy Institute, Popular Democracy, , Equifax Identity Defense, Legal defense teams, Bankruptcy advisors (failed attempts), Public relations firms, .
Type of Data Compromised: Home addresses, Email addresses
Number of Records Exposed: Hundreds
Sensitivity of Data: High
Personally Identifiable Information: Yes
Number of Records Exposed: 3225
Prevention of Data Exfiltration: The company takes the following measures to prevent data exfiltration: Proposed $9B global settlement (rejected), Preparation for upcoming trials, Federal case consolidation (NJ District Court), .
Handling of PII Incidents: The company handles incidents involving personally identifiable information (PII) through by product withdrawal (2023), replacement with cornstarch-based alternative, litigation defense strategy and .
Regulations Violated: Potential violations of consumer protection laws, Product liability statutes, Failure to disclose health risks (alleged),
Legal Actions: Class-action lawsuits, State/federal jury trials, Appeals of verdicts, Bankruptcy filings (3 failed attempts),
Ensuring Regulatory Compliance: The company ensures compliance with regulatory requirements through Class-action lawsuits, State/federal jury trials, Appeals of verdicts, Bankruptcy filings (3 failed attempts), .
Lessons Learned: Bankruptcy strategies may not shield against mass torts, Jury trials pose significant financial risks, Product liability claims can escalate rapidly post-bankruptcy rejection, Reputation damage extends beyond financial costs
Recommendations: Implement a crowdsourced database to identify potential misuse of opioid settlement funds, Encourage attorneys general to take an active oversight roleImplement a crowdsourced database to identify potential misuse of opioid settlement funds, Encourage attorneys general to take an active oversight role
Recommendations: Reevaluate settlement offers to mitigate long-term costs, Enhance transparency in product safety communications, Explore alternative dispute resolution mechanisms, Monitor state-level jury trends for risk assessmentReevaluate settlement offers to mitigate long-term costs, Enhance transparency in product safety communications, Explore alternative dispute resolution mechanisms, Monitor state-level jury trends for risk assessmentReevaluate settlement offers to mitigate long-term costs, Enhance transparency in product safety communications, Explore alternative dispute resolution mechanisms, Monitor state-level jury trends for risk assessmentReevaluate settlement offers to mitigate long-term costs, Enhance transparency in product safety communications, Explore alternative dispute resolution mechanisms, Monitor state-level jury trends for risk assessment
Key Lessons Learned: The key lessons learned from past incidents are Bankruptcy strategies may not shield against mass torts,Jury trials pose significant financial risks,Product liability claims can escalate rapidly post-bankruptcy rejection,Reputation damage extends beyond financial costs.
Source: KFF Health News
Source: Maine Office of the Attorney General
Source: US District Court for the District of New Jersey
Source: Johnson & Johnson Securities Filings (2024-09)
Additional Resources: Stakeholders can find additional resources on cybersecurity best practices at and Source: KFF Health News, and Source: Maine Office of the Attorney General, and Source: BloombergUrl: https://www.bloomberg.com/news/articles/2024-10-01/j-j-s-baby-powder-lawsuits-jump-17-after-bankruptcy-setbackDate Accessed: 2024-10-01, and Source: US District Court for the District of New JerseyUrl: https://www.njd.uscourts.gov/cases/case-information-re-johnson-johnson-talcum-powder-products-marketing-sales-practices-and, and Source: Johnson & Johnson Securities Filings (2024-09).
Investigation Status: Ongoing (active litigation in multiple jurisdictions)
Communication of Investigation Status: The company communicates the status of incident investigations to stakeholders through Public Statements Denying Talc-Asbestos Link, Emphasis On 100+ Years Of 'Safe Use' and Criticism Of Lawsuit 'Volume Over Merit'.
Stakeholder Advisories: Investor Updates Via Securities Filings, Legal Analyses By Bloomberg Intelligence, Academic Commentary (E.G., University Of Richmond).
Customer Advisories: Product withdrawal announcement (2023)No direct advisories on cancer risks
Advisories Provided: The company provides the following advisories to stakeholders and customers following an incident: were Investor Updates Via Securities Filings, Legal Analyses By Bloomberg Intelligence, Academic Commentary (E.G., University Of Richmond), Product Withdrawal Announcement (2023), No Direct Advisories On Cancer Risks and .
Root Causes: Alleged Failure To Warn Consumers Of Talc-Asbestos Risks, Aggressive Bankruptcy Tactics Backfiring, Jury Sympathy For Plaintiffs In Cancer Cases, Historical Product Marketing Practices,
Corrective Actions: Product Reformulation (Cornstarch), Litigation Defense Restructuring, Potential Future Settlement Negotiations,
Post-Incident Analysis Process: The company's process for conducting post-incident analysis is described as Opioid Policy Institute, Popular Democracy, , Equifax Identity Defense, Legal Defense Teams, Bankruptcy Advisors (Failed Attempts), Public Relations Firms, .
Corrective Actions Taken: The company has taken the following corrective actions based on post-incident analysis: Product Reformulation (Cornstarch), Litigation Defense Restructuring, Potential Future Settlement Negotiations, .
Most Recent Incident Detected: The most recent incident detected was on 2024-08-17.
Most Recent Incident Publicly Disclosed: The most recent incident publicly disclosed was on 2024-10-01T00:00:00Z.
Highest Financial Loss: The highest financial loss from an incident was {'current_settlements': '$3 billion (historical)', 'projected_total_cost': 'Up to $11 billion', 'recent_jury_award': '$966 million (California case, 2024-10)', 'legal_defense_costs': None}.
Most Significant Data Compromised: The most significant data compromised in an incident were Home addresses, Email addresses and .
Third-Party Assistance in Most Recent Incident: The third-party assistance involved in the most recent incident was opioid policy institute, popular democracy, , Equifax Identity Defense, legal defense teams, bankruptcy advisors (failed attempts), public relations firms, .
Containment Measures in Most Recent Incident: The containment measures taken in the most recent incident was Product withdrawal (2023)Replacement with cornstarch-based alternativeLitigation defense strategy.
Most Sensitive Data Compromised: The most sensitive data compromised in a breach were Home addresses and Email addresses.
Number of Records Exposed in Most Significant Breach: The number of records exposed in the most significant breach was 327.0.
Most Significant Legal Action: The most significant legal action taken for a regulatory violation was Class-action lawsuits, State/federal jury trials, Appeals of verdicts, Bankruptcy filings (3 failed attempts), .
Most Significant Lesson Learned: The most significant lesson learned from past incidents was Reputation damage extends beyond financial costs.
Most Significant Recommendation Implemented: The most significant recommendation implemented to improve cybersecurity was Enhance transparency in product safety communications, Monitor state-level jury trends for risk assessment, Implement a crowdsourced database to identify potential misuse of opioid settlement funds, Reevaluate settlement offers to mitigate long-term costs, Encourage attorneys general to take an active oversight role and Explore alternative dispute resolution mechanisms.
Most Recent Source: The most recent source of information about an incident are KFF Health News, US District Court for the District of New Jersey, Maine Office of the Attorney General, Johnson & Johnson Securities Filings (2024-09) and Bloomberg.
Most Recent URL for Additional Resources: The most recent URL for additional resources on cybersecurity best practices is https://www.bloomberg.com/news/articles/2024-10-01/j-j-s-baby-powder-lawsuits-jump-17-after-bankruptcy-setback, https://www.njd.uscourts.gov/cases/case-information-re-johnson-johnson-talcum-powder-products-marketing-sales-practices-and .
Current Status of Most Recent Investigation: The current status of the most recent investigation is Ongoing (active litigation in multiple jurisdictions).
Most Recent Stakeholder Advisory: The most recent stakeholder advisory issued was Investor updates via securities filings, Legal analyses by Bloomberg Intelligence, Academic commentary (e.g., University of Richmond), .
Most Recent Customer Advisory: The most recent customer advisory issued was an Product withdrawal announcement (2023)No direct advisories on cancer risks.
.png)
FreePBX Endpoint Manager is a module for managing telephony endpoints in FreePBX systems. Versions prior to 16.0.96 and 17.0.1 through 17.0.9 have a weak default password. By default, this is a 6 digit numeric value which can be brute forced. (This is the app_password parameter). Depending on local configuration, this password could be the extension, voicemail, user manager, DPMA or EPM phone admin password. This issue is fixed in versions 16.0.96 and 17.0.10.
Neuron is a PHP framework for creating and orchestrating AI Agents. In versions 2.8.11 and below, the MySQLWriteTool executes arbitrary SQL provided by the caller using PDO::prepare() + execute() without semantic restrictions. This is consistent with the name (“write tool”), but in an LLM/agent context it becomes a high-risk capability: prompt injection or indirect prompt manipulation can cause execution of destructive queries such as DROP TABLE, TRUNCATE, DELETE, ALTER, or privilege-related statements (subject to DB permissions). Deployments that expose an agent with MySQLWriteTool enabled to untrusted input and/or run the tool with a DB user that has broad privileges are impacted. This issue is fixed in version 2.8.12.
Neuron is a PHP framework for creating and orchestrating AI Agents. Versions 2.8.11 and below use MySQLSelectTool, which is vulnerable to Read-Only Bypass. MySQLSelectTool is intended to be a read-only SQL tool (e.g., for LLM agent querying, however, validation based on the first keyword (e.g., SELECT) and a forbidden-keyword list does not block file-writing constructs such as INTO OUTFILE / INTO DUMPFILE. As a result, an attacker who can influence the tool input (e.g., via prompt injection through a public agent endpoint) may write arbitrary files to the DB server if the MySQL/MariaDB account has the FILE privilege and server configuration permits writes to a useful location (e.g., a web-accessible directory). This issue is fixed in version 2.8.12.
Okta Java Management SDK facilitates interactions with the Okta management API. In versions 11.0.0 through 20.0.0, race conditions may arise from concurrent requests using the ApiClient class. This could cause a status code or response header from one request’s response to influence another request’s response. This issue is fixed in version 20.0.1.
The Auth0 Next.js SDK is a library for implementing user authentication in Next.js applications. When using versions 4.11.0 through 4.11.2 and 4.12.0, simultaneous requests on the same client may result in improper lookups in the TokenRequestCache for the request results. This issue is fixed in versions 4.11.2 and 4.12.1.
Get company history
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Identify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.
Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.
Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.
Leverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.
Rapid